Stereotactic radiotherapy of meningiomas: symptomatology, acute and late toxicity.

Department of Radiation Oncology, University of Giessen and Marburg, Germany.
Strahlentherapie und Onkologie (Impact Factor: 2.73). 08/2006; 182(7):382-8. DOI: 10.1007/s00066-006-1535-7
Source: PubMed

ABSTRACT Stereotactic radiosurgery (SRS) is well established in the treatment of skull base meningiomas, but this therapy approach is limited to small tumors only. The fractionated stereotactic radiotherapy (SRT) offers an alternative treatment option. This study aims at local control, symptomatology, and toxicity.
Between 1997-2003, 224 patients were treated with SRT (n = 183), hypofractionated SRT (n = 30), and SRS (n = 11). 95/224 were treated with SRT/SRS alone. 129/224 patients underwent previous operations. Freedom from progression and overall survival, toxicity, and symptomatology were evaluated systematically. Additionally, tumor volume (TV) shrinkage was analyzed three-dimensionally within the planning system.
The median follow-up was 36 months (range, 12-100 months). Overall survival and freedom from progression for 5 years were 92.9% and 96.9%. Quantitative TV reduction was 26.2% and 30.3% 12 and 18 months after SRT/SRS (p < 0.0001). 95.9% of the patients improved their symptoms or were stable. Clinically significant acute toxicity (CTC III degrees ) was rarely seen (2.5%). Clinically significant late morbidity (III degrees -IV degrees ) or new cranial nerve palsies did not occur.
SRT offers an additional treatment option of high efficacy with only few side effects. In the case of large tumor size (> 4 ml) and adjacent critical structures (< 2 mm), SRT is highly recommended.

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: To determine visual outcome including the occurrence of radiation induced optic neuropathy (RION) as well as tumor control after fractionated stereotactic radiation therapy (FSRT) of benign anterior skull base meningiomas or pituitary adenomas. Thirty-nine patients treated with FSRT for anterior skull base meningiomas and 55 patients treated with FSRT for pituitary adenomas between January 1999 and December 2009 with at least 2 years follow-up were included. Patients were followed up prospectively with magnetic resonance imaging scans, visual acuity and visual field examinations. RION was found in four (10 %) patients with anterior skull base meningiomas and seven patients (13 %) with pituitary adenomas. The five-year actuarial freedom from 25 % RION visual field loss was 94 % following FSRT. Actuarial 2-, 5- and 10-year tumor control rates were 100, 88.4 and 64.5 % for anterior skull base meningiomas and 100, 98.2 and 94.9 % for pituitary adenomas, respectively. Patients with an impaired visual field function pre-FSRT were more likely to experience worsened function (p = 0.016). We found that RION, was a relatively uncommon event, in a large prospective cohort of patients that were systematically monitored following FSRT of benign anterior skull base tumors. Long term tumor control was favorable, especially for pituitary adenomas.
    Journal of Neuro-Oncology 02/2014; · 3.12 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: To investigate the outcome of definitive stereotactic-based radiotherapy in elderly patients (⩾70years of age) with benign intracranial meningiomas. 121 patients were treated with either fractionated stereotactic radiotherapy (FRTS; n=74), hypofractionated FSRT (hFSRT; n=35) or stereotactic radiosurgery (SRS; n=12), depending on tumor size and location. Local control (LC), overall survival (OS), cause-specific survival (CSS), symptomatology and acute and late toxicity were assessed. The prognostic value of factors such as age, sex, tumor location, Karnofsky performance scale, target volume and radiotherapy schedule was examined. The median follow-up was 40months (range, 12-124months). LC, OS and CSS at 3years were 98.3%, 92% and 99% and at 5years they accounted 94.7%, 79% and 94.3%, respectively. We failed to identify any significant prognostic factor for outcome. Only Grade I-II toxicity was observed, whereas no new neurologic deficits or treatment-related mortality were encountered. This is the first study to assess the outcome following radiotherapy in elderly patients with intracranial meningiomas. The high local control, the low toxicity and the lack of treatment-associated mortality make stereotactic radiotherapy an attractive option in an age population where neurosurgery is often correlated with some mortality.
    Radiotherapy and Oncology 05/2014; · 4.86 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Purpose To investigate the long-term outcome of stereotactic-based radiation therapy in a large cohort of patients with benign intracranial meningiomas. Methods and Materials Between 1997 and 2010, 318 patients with histologically confirmed (44.7%; previous surgery) or imaging-defined (55.3%) benign meningiomas were treated with either fractionated stereotactic radiation therapy (79.6%), hypofractionated stereotactic radiation therapy (15.4%), or stereotactic radiosurgery (5.0%), depending on tumor size and location. Local control (LC), overall survival (OS), cause-specific survival (CSS), prognostic factors, and toxicity were analyzed. Results The median follow-up was 50 months (range, 12-167 months). Local control, OS, and CSS at 5 years were 92.9%, 88.7%, and 97.2%, and at 10 years they were 87.5%, 74.1%, and 97.2%, respectively. In the multivariate analysis, tumor location (P=.029) and age >66 years (P=.031) were predictors of LC and OS, respectively. Worsening of pre-existing neurologic symptoms immediately after radiation therapy occurred in up to 2%. Clinically significant acute toxicity (grade 3°) occurred in 3%. Only grade 1-2 late toxicity was observed in 12%, whereas no new neurologic deficits or treatment-related mortality were encountered. Conclusions Patients with benign meningiomas predominantly treated with standard fractionated stereotactic radiation therapy with narrow margins enjoy excellent LC and CSS, with minimal long-term morbidity.
    International journal of radiation oncology, biology, physics 01/2014; · 4.59 Impact Factor